412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors

• Ignacio Melero,
• Emiliano Calvo,
• Patricia LoRusso,
• Ravit Geva,
• Elena Garralda,
• Eytan Ben-Ami,
• Corinne Maurice-Dror,
• Michelle Niewood,
• Ulf Forssmann

Affiliations

Ignacio Melero

9Universidad de Navarra, Pamplona, Spain

Emiliano Calvo

4START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain

Patricia LoRusso

Aff10 0000 0001 1456 7807grid.254444.7Department of Hematology & OncologyKarmanos Cancer Institute, Wayne State University Detroit MI USA

Ravit Geva

Aff42 0000 0001 0518 6922grid.413449.fTel Aviv Sourasky Medical Center Tel-Aviv Israel

Elena Garralda

6Vall d’Hebron Institute of Oncology, Barcelona, Spain

Eytan Ben-Ami

3Chaim Sheba Medical Center, Ramat Gan, Israel

Corinne Maurice-Dror

4Institute of Oncology, Haifa, Israel

Michelle Niewood

8Genmab A/S, Princeton, NJ, USA

Ulf Forssmann

8Genmab A/S, Princeton, NJ, USA